




Amlan[®]
INTERNATIONAL



 **NeutraPath**



In Vitro and In Vivo Evaluation of Therapeutic Effects of NeutraPath™ Against *Salmonella* Typhimurium

H. Xue¹, D. Wang¹, M. Handtmann¹, B.M. Hargis², & G. Tellez²

¹ Amlan International, Chicago, IL, 60061, USA

² Department of Poultry Science, University of Arkansas, Fayetteville AR 72701, USA

Salmonella Infections


A Significant Public Health Concern

- In the US, 1.4 million cases of human salmonellosis annually; 100,000 cases due to antibiotic-resistant Salmonella
- Poultry serves as the major reservoir of Salmonellas
- Preharvest Salmonella control is of utmost importance;
- Feed additives are a key pre-harvest measure which can help control Salmonella at the farm level




Colonization in chicken intestinal tract

Central to Entry into the Human Food Chain




NeutraPath™

A natural antimicrobial



Antivirulence Strategy May Pinpoint a Paradigm Shift for Pathogen Control

- **Toxins**
- Adhesins
- **Biofilm formation**
- **Secretion systems**
(e.g., Type III Secretion systems)
- Cell-to-cell communication
 - **Quorum sensing**
- Siderophores
- Immune evasion




NeutraPath™

Proven Synergistic Formula


Bacteriocidal and
bacteriostatic effect

Neutralizing virulence factors


NeutraPath's minimum inhibitory concentration (MIC)



Ability of NeutraPath to Kill *Salmonella* in SIMULATED GI environment *in vitro*



NeutraPath reduced *Salmonella* Typhimurium bacterial load in the *in vitro* digestion system



In Vivo Validation

Objectives

To evaluate in vivo effects of NeutraPath on:


- *Salmonella enterica* sv. Typhimurium cecal colonization in broiler chickens;
- Functional integrity of the host's gut barrier

In Vivo Validation


Experimental Design

One-day old male broiler chicks were randomly allocated to one of three groups (n=30 chickens):


- Challenged control with non-treated feed
- NeutraPath supplemented at 0.25%
- NeutraPath supplemented at 0.5%



NeutraPath Reduced Prevalence of *Salmonella* Typhimurium in Ceca




NeutraPath Reduced *Salmonella* Typhimurium Bacterial Load in Ceca





Key Property of *Salmonella*

Ability to invade non-phagocytic epithelial cells




HilA-InvF Axis - Master Regulators For Salmonella Pathogenicity Island 1 (SPI1) TTSS Apparatus Gene Transcription



NeutraPath down-regulated *S. Typhimurium* *hilA* and *invF* mRNA expression at subinhibitory concentration (SIC)




NeutraPath's Suppression of HilA-InvF Axis Further Blocked Expression of Key Downstream Effectors Involved in Invasion




Tight junction:

Key Target of *Salmonella Typhimurium*



NeutraPath Reduced *In Vivo* Gut Permeability after *Salmonella* Typhimurium Challenge



Conclusions

- NeutraPath treatment had the therapeutic potential to reduce *S. Typhimurium* intestinal colonization in broiler chickens;
- Mechanistically, NeutraPath strikingly tuned down SPI-1 TTSS virulence machinery and modified the bacterial 'behaviors' to make them more benign;
- As a result of the blockade of SPI-1 virulence development, NeutraPath further preserved gut barrier integrity during *S. Typhimurium* challenge.



Thank you

Hongyu Xue MD, PhD

Life Sciences Director

Amlan International

hongyu.xue@amlan.com